Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA

By Wyatt L.S.   Whitehead S.S.   Venanzi K.A.   Murphy B.R.   Moss B.  

Vaccine, Vol. 18, Iss. 5, 1999-10 ,pp. : 392-397

Elsevier

Access to resources Recommend Favorite

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model

By Carroll M.W.   Overwijk W.W.   Chamberlain R.S.   Rosenberg S.A.   Moss B.   Restifo N.P.  

Vaccine, Vol. 15, Iss. 4, 1997-03 ,pp. : 387-394

Elsevier

Access to resources Recommend Favorite

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya

By Hanke T.   McMichael A.J.   Samuel R.V.   Powell L.A.J.   McLoughlin L.   Crome S.J.   Edlin A.  

Vaccine, Vol. 21, Iss. 1, 2002-11 ,pp. : 108-114

Elsevier

Access to resources Recommend Favorite

Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes

By Nam J.-H.   Wyatt L.S.   Chae S.-L.   Cho H.-W.   Park Y.-K.   Moss B.  

Vaccine, Vol. 17, Iss. 3, 1999-02 ,pp. : 261-268

Elsevier

Access to resources Recommend Favorite

DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice

By Ma X.   Forns X.   Gutierrez R.   Mushahwar I.K.   Wu T.   Payette P.J.   Bukh J.   Purcell R.H.   Davis H.L.  

Vaccine, Vol. 20, Iss. 27, 2002-09 ,pp. : 3263-3271

Elsevier

Access to resources Recommend Favorite